Skip to main content
OpenTrials
Completed

NCT Number: NCT02305420

EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage

EmbryoGen and BlastGen contain the cytokine growth factor Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), which has been documented to give significant benefit to this difficult group of patients.

Results showed a highly significant effect of 44% relative improvement in ongoing implantation rate (p=0.001) in women who have previously miscarried (Ziebe et al 2013).

We wish to undertake a randomised Controlled trial to determine if EmbryoGen/BlastGen media improves pregnancy outcomes in women with recurrent implantation failure, recurrent miscarriage and poor embryo development when compared to standard media.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–41 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

FertilitySA

Adelaide, South Australia, 5006, Australia

About this study

A randomised control pilot study will be undertaken for 100 women who have implantation failure (≥ 2 embryo transfers without a pregnancy) or at least 1 previous miscarriage and are having a further IVF cycle.

At oocyte retrieval each couple will be randomised using numbered envelopes containing pre randomised group allocations by a person uninvolved in the trial to:

  • BlastGen Group (n=50): culturing their embryos in ORIGIO standard, sequential culture mediums for 3 days (EmbryoGen included) then BlastGen media (GM-CSF containing media) for remaining 2 days or
  • Standard Media Group (n=50): culturing their embryos in Cook standard sequential medium for 5 days.

The best single embryo will be transferred on day 5.

The clinical staff and participating couple will be blinded as to whether BlastGen or standard media was used in culture to day 5. Fertility SA embryologists will not be blind as to which study group a couple is in and which media is being used. The embryos will be cultured using the usual methods and lab facilities by Fertility SA's current embryology staff members who will not be blind to the media being used.

Records on the outcome of the oocyte fertilisation, blastocyst development, implantation rate and pregnancy rates will be recorded, as is standard practice. Pregnancy scans will be carried out at 7 and 12 weeks. Live birth outcomes and any congenital anomalies will be recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women undertaking an IVF or ICSI cycle
  • aged between 25 and 41 years
  • 2 or more embryos transferred without a positive pregnancy outcome OR a history of at least 1 previous pregnancy loss, OR
  • Poor embryo development (<20% of embryo developing on time at Day 3 or no blastocyst above Grade 2 on Day 5)

Exclusion criteria

  • male partner requiring surgical retrieval of sperm except in cases of previous vasectomy
  • the use of another investigational drug within 30 days
  • any severe chronic disease that would significantly influence an IVF cycle
  • less than 3 follicles>14mm on ultrasound on the day of HCG trigger

Treatment and study plan

EmbryoGen/ BlastGen media

Device

Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)

Other names: GM-CSF containing media

Standard Cook sequential media

Device

Standard Cook IVF media will be used in the control arm

Primary outcomes

  1. Livebirth >20 weeks

    Time frame: 9 months after closure of trial (18 +9 months)

    Any delivery >20 resulting in a livebirth

Secondary outcomes

  1. Congenital Anomaly Rate

    Time frame: 9 months after closure of trial (18 +9 months)

    number of liveborns with a congenital anomaly

  2. Clinical pregnancy rates at 7 and 12 weeks gestation

    Time frame: 18 months

    Fetal Heart Beat seen on Ultrasound scan at 7 and 12 weeks

  3. Number of embryos reaching blastocyst stage

    Time frame: 18 months

    Number of blastocysts per cycle

  4. Day 3 and day 5 embryo scores

    Time frame: 18 months

    grade of day 3 and day 5 embryos

  5. Cryopreservation outcomes

    Time frame: 18 months

    Number of Frozen blastocysts

Sponsors and collaborators

Lead sponsor

FertilitySA

Industry

Collaborators

  • University of Adelaide

Registry information

Acronym: BlastGen

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Dec 2, 2014
Registry last updated
Feb 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.